Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1977

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 1977
---
22,764,764 shares issued and outstanding at December 31, 2023 
     -  
     38,023,784 
  
    Total convertible preferred stock 
     -  
     42,101,344 

    Stockholders’ deficit: 

    Series C convertible preferred stock, $0.0001 par value;2,853 shares
authorized; 2,853 issued and outstanding at December 31, 2024; liquidation preference of $2,853,000 
     1,249,999  
     - 
  
    Series A convertible preferred stock, $0.0001 par value; 12,580 shares
authorized; 1,894 issued and outstanding at December 31, 2024; liquidation preference of $1,894,000 
     1,708,396  
     - 
  
    Series B convertible preferred stock, $0.0001 par value; 626 shares
authorized; 273 issued and outstanding at December 31, 2024; liquidation preference of $273,000 
     218,051  
     - 
  
    Class A common stock; $0.0001 par value; 1,000,000,000 shares authorized; 2,415,883 shares issued and outstanding at December 31, 2024 
     242  
     - 
  
    Common stock, $0.0001 par value, 45,350,000 shares authorized, 5,845 shares issued and outstanding at December 31, 2023 
     -  
     1 
  
    Additional paid-in capital 
     67,142,046  
     1,032,125 
  
    Stock subscription receivable 
     (1,295,444) 
     - 
  
    Accumulated deficit 
     (70,917,853) 
     (43,089,821)
  
    Total stockholders’ deficit 
     (1,894,563) 
     (42,057,695)
  
    Total liabilities, convertible preferred stock and stockholders’ deficit 
    $6,206,929
    $5,126,302 

See
accompanying notes to the consolidated financial statements

Reflects a 1-for-100 reverse stock split effective
January 8,